The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus : a systematic review and meta-analysis of clinical trials
© 2021. The Author(s), under exclusive licence to Springer Nature B.V..
PURPOSE: This systematic review and meta-analysis aimed to assess renal function and cardiometabolic biomarkers after treatment with beraprost sodium in patients with diabetes mellitus.
METHODS: We systemically searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library up to August 2020. Statistical heterogeneities were computed using Cochrane's Q test and I2 test. A fixed- or random-effects model was used to calculate the weighted mean difference (WMD) and corresponding 95% confidence intervals (CI).
RESULTS: From 341citations, seven trials were included into our meta-analysis. Our findings demonstrated that beraprost sodium intake significantly decreased blood urea nitrogen (BUN) (WMD = -5.62, 95% CI [-8.49, -2.74], P < 0.001) and cystatin C (WMD = -0.57, 95% CI [-0.68, -0.46], P < 0.001). Beraprost sodium intake had no significant effect on fasting blood sugar (FBS), hemoglobin A1c (HbA1c), cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, systolic blood pressure (SBP), diastolic blood pressure (DBP), and creatinine (Cr) in patients with diabetes receiving beraprost sodium in comparison with the controls.
CONCLUSION: Our meta-analysis revealed that beraprost sodium administration significantly decreased BUN and cystatin C levels in patients with diabetes. However, no significant effect was observed on the cardiometabolic profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
International urology and nephrology - 54(2022), 1 vom: 21. Jan., Seite 111-120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nowrouzi-Sohrabi, Peyman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
35E3NJJ4O6 |
|---|
| Anmerkungen: |
Date Completed 24.02.2022 Date Revised 24.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11255-021-02887-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325685673 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325685673 | ||
| 003 | DE-627 | ||
| 005 | 20231225192948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11255-021-02887-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325685673 | ||
| 035 | |a (NLM)34019221 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nowrouzi-Sohrabi, Peyman |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus |b a systematic review and meta-analysis of clinical trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2022 | ||
| 500 | |a Date Revised 24.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Nature B.V. | ||
| 520 | |a PURPOSE: This systematic review and meta-analysis aimed to assess renal function and cardiometabolic biomarkers after treatment with beraprost sodium in patients with diabetes mellitus | ||
| 520 | |a METHODS: We systemically searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library up to August 2020. Statistical heterogeneities were computed using Cochrane's Q test and I2 test. A fixed- or random-effects model was used to calculate the weighted mean difference (WMD) and corresponding 95% confidence intervals (CI) | ||
| 520 | |a RESULTS: From 341citations, seven trials were included into our meta-analysis. Our findings demonstrated that beraprost sodium intake significantly decreased blood urea nitrogen (BUN) (WMD = -5.62, 95% CI [-8.49, -2.74], P < 0.001) and cystatin C (WMD = -0.57, 95% CI [-0.68, -0.46], P < 0.001). Beraprost sodium intake had no significant effect on fasting blood sugar (FBS), hemoglobin A1c (HbA1c), cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, systolic blood pressure (SBP), diastolic blood pressure (DBP), and creatinine (Cr) in patients with diabetes receiving beraprost sodium in comparison with the controls | ||
| 520 | |a CONCLUSION: Our meta-analysis revealed that beraprost sodium administration significantly decreased BUN and cystatin C levels in patients with diabetes. However, no significant effect was observed on the cardiometabolic profile | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Beraprost sodium | |
| 650 | 4 | |a Cardiometabolic | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Renal function | |
| 650 | 4 | |a Systematic review | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a beraprost |2 NLM | |
| 650 | 7 | |a 35E3NJJ4O6 |2 NLM | |
| 650 | 7 | |a Epoprostenol |2 NLM | |
| 650 | 7 | |a DCR9Z582X0 |2 NLM | |
| 700 | 1 | |a Tabrizi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Hessami, Kamran |e verfasserin |4 aut | |
| 700 | 1 | |a Shabani-Borujeni, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini-Bensenjan, Mahnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Shahla |e verfasserin |4 aut | |
| 700 | 1 | |a Jalali, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Keshavarz, Pedram |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadizar, Fariba |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International urology and nephrology |d 1971 |g 54(2022), 1 vom: 21. Jan., Seite 111-120 |w (DE-627)NLM000017531 |x 1573-2584 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:1 |g day:21 |g month:01 |g pages:111-120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11255-021-02887-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 1 |b 21 |c 01 |h 111-120 | ||